Cerebrospinal fluid biomarkers in Parkinson disease
Open accessAbstract
Clinical diagnosis of Parkinson disease (PD) is difficult in early stages of disease, with high risk of misdiagnosis. The long preclinical phase of PD provides the possibility for early therapeutic intervention once disease-modifying therapies have been developed, but lack of biomarkers for early diagnosis and monitoring of disease progression represents a major obstacle to achievement of this goal. Accordingly, research efforts aimed at identification of novel biomarkers have been increasing in the past 5 years. Cerebrospinal fluid (CSF) is an accessible source of brain-derived proteins, which mirror molecular changes that take place in the CNS. In this Review, we discuss evidence from numerous studies that have focused on identification of candidate CSF biomarkers for PD. Notably, molecular pathways related to α-synuclein, tau and β-amyloid peptides have received considerable attention. CSF levels of the protein DJ-1 are also of interest, although further investigation of this candidate marker is required. These studies support the usefulness of a combination of various CSF biomarkers of PD to increase diagnostic accuracy during early phases of the disease, and to differentiate PD from other neurodegenerative disorders.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Attempts to discover new biomarkers for the diagnosis of early stages of the disease are ongoing.
“Attempts to discover new biomarkers for the diagnosis of early stages of the disease are ongoing [134–136].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [136]
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · see citing works
Autophagy in the Pathogenesis of Disease
Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069 · see citing works
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · see citing works
Autophagy: process and functionPreprint
Mizushima, N. (2007) · Genes & Development · doi:10.1101/gad.1599207 · Cited by 3,967 · see citing works
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836 · see citing works
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 3,151 · see citing works
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibáñez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,800 · see citing works
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737 · see citing works
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,245 · see citing works
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135 · see citing works
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029 · see citing works
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956 · see citing works
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón‐Sánchez, J., Schulte, C., Brás, J., Sharma, M., Gibbs, J. R., Berg, D., Paisán‐Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,916 · see citing works
The Parkinson Progression Marker Initiative (PPMI)
MAREK, K. L., Jennings, D. L., Lasch, S., Siderowf, A. D., Tanner, C. M., Simuni, T., Coffey, C. S., Kieburtz, K. D., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,888 · see citing works
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works
In vivo demonstration that α-synuclein oligomers are toxic
Winner, B., Jappelli, R., Maji, S. K., Desplats, P., Boyer, L. F., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100976108 · Cited by 1,487 · see citing works
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341 · see citing works
Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,308 · see citing works
Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions
Picotti, P., & Aebersold, R. (2012) · Nature Methods · doi:10.1038/nmeth.2015 · Cited by 1,302 · see citing works
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263 · see citing works
Identification of two distinct synucleins from human brain
Jakes, R., Spillantini, M. G., & Goedert, M. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00395-5 · Cited by 1,080 · see citing works
The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
Hansen, L., Salmon, D., Galasko, D., Masliah, E., Katzman, R., DeTeresa, R., Thal, L., Pay, M. M., Hofstetter, R., Klauber, M., et al. (1990) · Neurology · doi:10.1212/wnl.40.1.1 · Cited by 1,068 · see citing works
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M. T., Michel, P. P., Marquez, J., Prigent, A., Ruberg, M., Hirsch, É. C., & Agid, Y. (1997) · PubMed · Cited by 1,045 · see citing works
Spillantini, M. G., Crowther, R. A., Jakes, R., Cairns, N. J., Lantos, P. L., & Goedert, M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00504-7 · Cited by 1,026 · see citing works
Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Science · doi:10.1126/science.1082324 · Cited by 879 · see citing works
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825 · see citing works
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789 · see citing works
Conway, K. A., Harper, J. D., & Lansbury, P. T. (2000) · Biochemistry · doi:10.1021/bi991447r · Cited by 786 · see citing works
Xu, J., Kao, S., Lee, F. J. S., Song, W., Jin, L., & Yankner, B. A. (2002) · Nature Medicine · doi:10.1038/nm0602-600 · Cited by 757 · see citing works
Vogiatzi, T., Xilouri, M., Vekrellis, K., & Stefanis, L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801992200 · Cited by 683 · see citing works
Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest Study
Aarsland, D., Brønnick, K., Larsen, J. P., Tysnes, O. B., & Alves, G. (2009) · Neurology · doi:10.1212/01.wnl.0000338632.00552.cb · Cited by 625 · see citing works
Mollenhauer, B., Locascio, J. J., Schulz‐Schaeffer, W., Sixel‐Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 623 · see citing works
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615 · see citing works
Phenotype, diagnosis, and treatment of Gaucher's disease.
Grabowski, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61522-6 · Cited by 582 · see citing works
Clinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q., & LaFerla, F. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0490-10.2010 · Cited by 576 · see citing works
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · see citing works
The epidemiology of dementia associated with Parkinson disease
Aarsland, D., & Kurz, M. W. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.034 · Cited by 572 · see citing works
Fauvet, B., Mbefo, M. K., Fares, M.-B., Desobry, C., Michael, S. A., Ardah, M. T., Tsika, E., Coune, P., Prudent, M., Lion, N., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.318949 · Cited by 565 · see citing works
Self-citationSharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., & Selkoe, D. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00024-2 · Cited by 562 · see citing works
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El‐Agnaf, O. M. A., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 556 · see citing works
Self-citationGlucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains
Gegg, M. E., Burke, D., Heales, S., Cooper, J., Hardy, J., Wood, N., & Schapira, A. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 551 · see citing works
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El‐Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 526 · see citing works
Self-citationA soluble α-synuclein construct forms a dynamic tetramer
Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L. T. T., Liao, J., Auclair, J. R., Johnson, D., Landeru, A., Simorellis, A. K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113260108 · Cited by 478 · see citing works
Zhu, J.-H., Horbinski, C., Guo, F.-L., Watkins, S. C., Uchiyama, Y., & Chu, C. T. (2007) · American Journal of Pathology · doi:10.2353/ajpath.2007.060524 · Cited by 469 · see citing works
Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway
Lee, H.-J., Khoshaghideh, F., Patel, S., & Lee, S.-J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3809-03.2004 · Cited by 445 · see citing works
Chen, Y., McMillan‐Ward, E., Kong, J., Israels, S. J., & Gibson, S. B. (2007) · Journal of Cell Science · doi:10.1242/jcs.011163 · Cited by 444 · see citing works
Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., Locascio, J. J., Schlossmacher, M. G., & El-Agnaf, O. M. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.024 · Cited by 425 · see citing works
Self-citationCerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
Shi, M. Y., Bradner, J. M., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 418 · see citing works
Occurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401 · see citing works
Cataldo, A. M., Barnett, J. L., Pieroni, C., & Nixon, R. A. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-16-06142.1997 · Cited by 393 · see citing works
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · see citing works
Self-citationCSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
Siderowf, A. D., Xie, S. X., Hurtig, H. I., Weintraub, D. A., Duda, J. E., Chen‐Plotkin, A. S., Shaw, L. M. J., Deerlin, V. M. V., Trojanowski, J. Q., & Clark, C. N. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 379 · see citing works
Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., Abbruzzese, G., & Tabaton, M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01153-8 · Cited by 363 · see citing works
El‐Agnaf, O. M. A., Jakes, R., Curran, M. D., Middleton, D., Ingenito, R., Bianchi, E., Pessi, A., Neill, D., & Wallace, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01418-5 · Cited by 363 · see citing works
Self-citationPathological roles of α-synuclein in neurological disorders
Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J., & Stefanis, L. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70213-7 · Cited by 359 · see citing works
Calabresi, P., Picconi, B., Parnetti, L., & Filippo, M. D. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70600-7 · Cited by 337 · see citing works
Self-citationDifferences in neuropathologic characteristics across the Lewy body dementia spectrum
Ballard, C., Ziabreva, I., Perry, R., Larsen, J. P., O'Brien, J., McKeith, I., Perry, E., & Aarsland, D. (2006) · Neurology · doi:10.1212/01.wnl.0000249130.63615.cc · Cited by 335 · see citing works
Phosphorylated α-Synuclein in Parkinson’s Disease
Wang, Y., Shi, M. Y., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M. ‐., Siderowf, A. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002566 · Cited by 281 · see citing works
Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress
Dagda, R., Zhu, J.-H., Kulich, S., & Chu, C. T. (2008) · Autophagy · doi:10.4161/auto.6458 · Cited by 280 · see citing works
Hashimoto, M., Hsu, L. J., Sisk, A., Xia, Y., Takeda, A., Sundsmo, M. P., & Masliah, E. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00514-9 · Cited by 267 · see citing works
Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease
Jellinger, K. A., & Attems, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0347-5 · Cited by 265 · see citing works
CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases
Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J. J., Kenney, C., Chung, K. A., Millard, S. P., Nutt, J. G., & Montine, T. J. (2008) · American Journal of Clinical Pathology · doi:10.1309/w01y0b808emeh12l · Cited by 263 · see citing works
El‐Agnaf, O. M. A., Jakes, R., Curran, M. D., & Wallace, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01419-7 · Cited by 258 · see citing works
Self-citationParkinson's disease subtypes: lost in translation?
Marras, C., & Lang, A. E. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303455 · Cited by 253 · see citing works
Paleologou, K. E., Kragh, C. L., Mann, D. M. A., Salem, S. A., Al‐Shami, R., Allsop, D., Hassan, A. H. M., Jensen, P. H., & El‐Agnaf, O. M. A. (2008) · Brain · doi:10.1093/brain/awn349 · Cited by 225 · see citing works
Self-citationThe risk of Parkinson's disease in type 1 Gaucher disease
Bultron, G., Kacena, K. A., Pearson, D., Boxer, M. A., Yang, R., Sathe, S. A., Pastores, G. M., & Mistry, P. K. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9055-0 · Cited by 223 · see citing works
Alves, G. W., Brønnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C. G., Kurz, M. W., Andréasson, U., Tysnes, O., Larsen, J. O., et al. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199950 · Cited by 221 · see citing works
Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P., Klafki, H., Sparbier, K., Av, S., Cepek, L., Trenkwalder, C., Rüther, E., et al. (2006) · Brain · doi:10.1093/brain/awl063 · Cited by 209 · see citing works
Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?
Öhrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., & Zetterberg, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.015 · Cited by 198 · see citing works
Park, M., Cheon, S., Bae, H.-R., Kim, S.-H., & Kim, J. W. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.4.215 · Cited by 195 · see citing works
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease
Waragai, M., Wei, J., Fujita, M., Nakai, M., Ho, G. J., Masliah, E., Akatsu, H., Yamada, T., & Hashimoto, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.011 · Cited by 195 · see citing works
Waxman, E. A., & Giasson, B. I. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0297-11.2011 · Cited by 193 · see citing works
Lee, V. M. ‐., Giasson, B. I., & Trojanowski, J. Q. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.01.007 · Cited by 185 · see citing works
Compta, Y., Martı́, M. J., Ibarretxe‐Bilbao, N., Junqué, C., Valldeoriola, F., Muñoz, E., Ezquerra, M., Ríos, J., & TOLOSA, E. S. (2009) · Movement Disorders · doi:10.1002/mds.22594 · Cited by 185 · see citing works
CSF Aβ42 and tau in Parkinson's disease with cognitive impairment
Montine, T. J., Shi, M. Y., Quinn, J. F., Peskind, E. R., Craft, S., Ginghină, C., Chung, K. A., Kim, H., Galasko, D. R., Jankovic, J. J., et al. (2010) · Movement Disorders · doi:10.1002/mds.23287 · Cited by 182 · see citing works
Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D’Amore, C., Pierguidi, L., Tambasco, N., Rossi, A., & Calabresi, P. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.016 · Cited by 173 · see citing works
Self-citationPreclinical Biomarkers of Parkinson Disease
Wu, Y., Le, W., & Jankovic, J. J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.321 · Cited by 173 · see citing works
Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias
Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., Carlo, C. D., Qureshi, M. M., Ardah, M. T., Varghese, S., Bonanni, L., Borroni, B., et al. (2011) · Movement Disorders · doi:10.1002/mds.23670 · Cited by 170 · see citing works
Self-citationIn vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia
Burack, M. A., Hartlein, J. M., Flores, H., Taylor-Reinwald, L., Perlmutter, J. S., & Cairns, N. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c7da8e · Cited by 163 · see citing works
Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond
Shachar, T., Bianco, C. L., Recchia, A., Wießner, C., Raas‐Rothschild, A., & Futerman, A. H. (2011) · Movement Disorders · doi:10.1002/mds.23774 · Cited by 150 · see citing works
Sjögren, M. J. C., Davidsson, P., Wallin, A., Granérus, A., Grundström, E., Askmark, H., Vanmechelen, E., & Blennow, K. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000048642 · Cited by 145 · see citing works
The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders
Velayati, A., Yu, W. H., & Sidransky, E. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0102-x · Cited by 145 · see citing works
Exploring the link between glucocerebrosidase mutations and parkinsonism
Westbroek, W., Gustafson, A. M., & Sidransky, E. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.003 · Cited by 144 · see citing works
Neuropathological Aspects of Alzheimer Disease, Parkinson Disease and Frontotemporal Dementia
Jellinger, K. A. (2008) · Neurodegenerative Diseases · doi:10.1159/000113679 · Cited by 137 · see citing works
[11C]PIB binding in Parkinson's disease dementia
Maetzler, W., Reimold, M., Liepelt, I., Solbach, C., Leyhe, T., Schweitzer, K. J., Eschweiler, G. W., Mittelbronn, M. G. A., Gaenslen, A., Uebele, M., et al. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.072 · Cited by 137 · see citing works
Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., Schindehütte, J., Poser, S., Wiltfang, J., & Otto, M. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000094871 · Cited by 131 · see citing works
CSF α-synuclein does not differentiate between parkinsonian disorders
Aerts, M., Esselink, R. A. J., Abdo, W. F., Bloem, B. R., & Verbeek, M. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.001 · Cited by 126 · see citing works
Wang, Y., Hancock, A. M., Bradner, J. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D. R., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.006 · Cited by 121 · see citing works
Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., & Murano, T. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31823899cc · Cited by 121 · see citing works
Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease
Balducci, C., Pierguidi, L., Persichetti, E., Parnetti, L., Sbaragli, M., Tassi, C., Orlacchio, A., Calabresi, P., Beccari, T., & Rossi, A. (2007) · Movement Disorders · doi:10.1002/mds.21399 · Cited by 116 · see citing works
Self-citationInteractions of Amyloidogenic Proteins
Giasson, B. I., Lee, V. M. ‐., & Trojanowski, J. Q. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:49 · Cited by 106 · see citing works
Foulds, P. G., Yokota, O., Thurston, A., Davidson, Y. S., Ahmed, Z., Holton, J. L., Thompson, J. C., Akiyama, H., Arai, T., Hasegawa, M., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.003 · Cited by 101 · see citing works
Lysosome‐associated membrane protein 1 (LAMP‐1) in Alzheimer’s disease
Barrachina, M., Maes, T., Buesa, C., & Ferrer, I. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00756.x · Cited by 97 · see citing works
Changing Concepts of Alzheimer Disease
McKhann, G. M. (2011) · JAMA · doi:10.1001/jama.2011.810 · Cited by 94 · see citing works
Cerebrospinal Fluid α-Synuclein Does Not Discriminate Between Dementia Disorders
Spies, P. E., Melis, R. J. F., Sjögren, M. J. C., Rikkert, M. G. M. O., & Verbeek, M. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0955 · Cited by 93 · see citing works
CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease
Noguchi‐Shinohara, M., Tokuda, T., Yoshita, M., Kasai, T., Ono, K., Nakagawa, M., El‐Agnaf, O. M. A., & Yamada, M. (2008) · Brain Research · doi:10.1016/j.brainres.2008.11.055 · Cited by 92 · see citing works
Self-citationClark, L. N., Nicolai, A., Afridi, S. K., Harris, J. M., Mejia‐Santana, H., Strug, L. J., COTE, L. J., Louis, E. D., Andrews, H., Waters, C., et al. (2004) · Movement Disorders · doi:10.1002/mds.20320 · Cited by 89 · see citing works
Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy
Marco, E. V. D., Annesi, G., Tarantino, P., Rocca, F. E., Provenzano, G., Civitelli, D., Candiano, I. C. C., Annesi, F., Carrideo, S., Condino, F., et al. (2007) · Movement Disorders · doi:10.1002/mds.21892 · Cited by 83 · see citing works
Sierks, M. R., Chatterjee, G., McGraw, C. E., Kasturirangan, S., Schulz, P., & Prasad, S. (2011) · Integrative Biology · doi:10.1039/c1ib00018g · Cited by 83 · see citing works
Cherin, P., Rosé, C., Serratrice, J., et al. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9095-5 · Cited by 78 · see citing works
Leverenz, J. B., Watson, G. S., Shofer, J., Zabetian, C. P., Zhang, J., & Montine, T. J. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.10.003 · Cited by 75 · see citing works
Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotype–genotype correlation
Aharon‐Peretz, J., Badarny, S., Rosenbaum, H., & Gershoni‐Baruch, R. (2005) · Neurology · doi:10.1212/01.wnl.0000176987.47875.28 · Cited by 75 · see citing works
Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach
van Dijk, K. D., Teunissen, C. E., Drukarch, B., Jiménez, C. R., Groenewegen, H. J., Berendse, H. W., & van de Berg, W. D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.04.020 · Cited by 72 · see citing works
Andersson, M., Zetterberg, H., Minthon, L., Blennow, K., & Londos, E. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2496 · Cited by 71 · see citing works
CSF markers of neurodegeneration in Parkinson’s disease
Vranová, H. P., Mareš, J., Nevrlý, M., Stejskal, D., Zapletalová, J., Hluštı́k, P., & Kaňovský, P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0462-z · Cited by 67 · see citing works
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies
Parnetti, L., Balducci, C., Pierguidi, L., Carlo, C. D., Peducci, M., D’Amore, C., Padiglioni, C., Mastrocola, S., Persichetti, E., Paciotti, S., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.03.002 · Cited by 67 · see citing works
Self-citationCerebrospinal fluid amyloid- and phenotypic heterogeneity in de novo Parkinson's disease
Alves, G. W., Pedersen, K. F., Bloem, B. R., Blennow, K., Zetterberg, H., Borm, G. F., Dalaker, T. O., Beyer, M. K., Aarsland, D., Andréasson, U., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303808 · Cited by 66 · see citing works
Masliah, E. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3117 · Cited by 66 · see citing works
Association between Parkinson's disease and glucocerebrosidase mutations in Brazil
Spitz, M., Rozenberg, R., Pereira, L. V., & Barbosa, E. R. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.06.010 · Cited by 65 · see citing works
Lehnert, S., Jesse, S., Rist, W., Steinacker, P., Soininen, H. S., Herukka, S., Tumani, H., Lenter, M., Oeckl, P., Ferger, B., et al. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.024 · Cited by 63 · see citing works
Soluble oligomers for the diagnosis of neurodegenerative diseases
El‐Agnaf, O. M. A., Walsh, D. M., & Allsop, D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00481-2 · Cited by 50 · see citing works
Self-citationSun, Q., Guo, J., Wang, L., et al. (2010) · Movement Disorders · doi:10.1002/mds.23009 · Cited by 50 · see citing works
Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes
Bech, S., Hjermind, L. E., Salvesen, L., Nielsen, J. E., Heegaard, N. H. H., Jørgensen, H. L., Rosengren, L., Blennow, K., Zetterberg, H., & Winge, K. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.08.012 · Cited by 47 · see citing works
Biochemical premotor biomarkers for Parkinson's disease
Mollenhauer, B., & Zhang, J. (2012) · Movement Disorders · doi:10.1002/mds.24956 · Cited by 44 · see citing works
Wu, G., Yan, B., Wang, X., Feng, X., Zhang, A., Xu, X., & Dong, H. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.04.011 · Cited by 42 · see citing works
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function
Shi, M. Y., Furay, A. R., Sossi, V., Aasly, J. O., Armaly, J., Wang, Y., Wszołek, Z. K., Uitti, R. J., Hasegawa, K., Yokoyama, T., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.015 · Cited by 39 · see citing works
Tozzi, A., Costa, C., Siliquini, S., Tantucci, M., Picconi, B., Kurz, A., Gispert, S., Auburger, G. W. J., & Calabresi, P. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.002 · Cited by 38 · see citing works
Self-citationAmyloid-β and τ biomarkers in Parkinson's disease–dementia
Buongiorno, M., Compta, Y., & Martı́, M. J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.06.046 · Cited by 38 · see citing works
Mollenhauer, B., Bibl, M., Esselmann, H., et al. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0629-4 · Cited by 35 · see citing works
DEEP BRAIN STIMULATION OF THE GLOBUS PALLIDUS FOR GENERALIZED DYSTONIA IN GM1 TYPE 3 GANGLIOSIDOSIS
Roze, E. F., Navarro, S., Cornu, P., et al. (2006) · Neurosurgery · doi:10.1227/01.neu.0000245620.24603.1b · Cited by 31 · see citing works
Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson’s disease
Vranová, H. P., Mareš, J., Hluštı́k, P., Nevrlý, M., Stejskal, D., Zapletalová, J., Obereignerů, R., & Kaňovský, P. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0708-4 · Cited by 31 · see citing works
Maetzler, W., Stoycheva, V., Schmid, B., Schulte, C., Hauser, A., Brockmann, K., Melms, A., Gasser, T., & Berg, D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101197 · Cited by 25 · see citing works
Problems Associated With Fluid Biomarkers for Parkinson‘s Disease
Nyhlén, J., Constantinescu, R., & Zetterberg, H. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.84 · Cited by 18 · see citing works
CSF biomarkers in different phenotypes of Parkinson disease
Jellinger, K. A. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0736-0 · Cited by 17 · see citing works
Decreased Expression of Lysosomal Alpha-Galactosiase A Gene in Sporadic Parkinson’s Disease
Wu, G., Huang, J. A., Feng, X., Zhang, A., Li, J., Pang, S., Gu, K., Dong, H., Zhang, J., Gao, H., et al. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0516-0 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750 · see citing works
Diagnosing progressive supranuclear palsy: Role of biological and neuroimaging markers
Benussi A, B. B. (2014) · Journal of Alzheimer's Disease & Parkinsonism · doi:10.4172/2161-0460.1000168 · Cited by 6 · see citing works
- Authors
- Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P.
- Affiliations
- University of Perugia (IT)
- Cancer Center Amsterdam (NL)
- Corresponding author
- Parnetti, Lucilla
- Venue
- Nature Reviews Neurology
- Published
- 2013-02-19
- Volume
- 9
- Issue
- 3
- Pages
- 131-140
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- OpenAlex
- W2148575698
- Cited by
- 209
- References
- 127
- Citations by year
- 2026: 3 · 2025: 16 · 2024: 11 · 2023: 13 · 2022: 12 · 2021: 15 · 2020: 18 · 2019: 12 · 2018: 15 · 2017: 15 · 2016: 21 · 2015: 23 · 2014: 25 · 2013: 10
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- green
- zenodo.org
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- VU Research Portal (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Keywords
- Parkinson's disease, cerebrospinal fluid biomarkers, alpha-synuclein, amyloid-beta, tau protein, DJ-1, early diagnosis, disease-modifying therapy, combined biomarker detection
- MeSH terms
- Protein Deglycase DJ-1, Humans, Intermediate Filament Proteins, Parkinson Disease, Biomarkers, Oncogene Proteins, Amyloid beta-Peptides, Disease Progression, Intracellular Signaling Peptides and Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
